CAPTRUST Financial Advisors
RLMD icon

CAPTRUST Financial Advisors’s Relmada Therapeutics RLMD Stock Holding History

CAPTRUST Financial Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,344
Closed -$26K – 3633
2022
Q2 		$26K Buy
1,344
+1,286
+2,217% +$28.1K ﹤0.01% 3226
2022
Q1 		$2K Buy
+58
New +$1.2K ﹤0.01% 4533

Other funds holding RLMD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

CAPTRUST Financial Advisors's RLMD Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Relmada Therapeutics (RLMD) in Q3 2022, closing a stake of 1,344 shares — an estimated $26K sold.

CAPTRUST Financial Advisors first reported a position in RLMD in Q1 2022 and held it in 2 quarters. The position peaked at $26K in Q2 2022. 134 funds tracked by Wall St. Rank hold RLMD as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Relmada Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 1,344 Relmada Therapeutics shares in Q3 2022, an estimated $26K.
  • CAPTRUST Financial Advisors first reported a position in Relmada Therapeutics in Q1 2022 and held it in 2 quarters.
  • CAPTRUST Financial Advisors's Relmada Therapeutics position peaked at $26K in Q2 2022.
  • 134 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.